Advanced PET and MRI techniques for improved therapy response assessment in diffuse large B-cell lymphoma / follicular lymphoma grade 3B
- Conditions
- Diffuse large B-cell lymphoma / follicular lymphoma grade 3Blymph node cancer10025320
- Registration Number
- NL-OMON40554
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 110
- Male or female patients
- Age: 18 years and older
- Histologically proven diffuse large B-cell lymphoma / Follicular lymphoma grade 3B
- Patients scheduled to undergo front-line R-CHOP 21 therapy
- Patients must be capable of giving written informed consent and the consent must have been obtained before the study-related procedures
- General contraindications for MRI (including cardiac pacemakers and claustrophobia). - Previous malignancy. However, subjects who have been free of malignancy for at least 5 years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible. - Diffuse large B-cell lymphoma / follicular lymphoma grade 3B central nervous system involvement. - Diffuse large B-cell lymphoma / follicular lymphoma grade 3B stage I disease. - HIV positivity (de novo or active) - Pregnant or lactating women. - Therapy has already started before pretreatment dual-time point 18F-FDG PET and DWI scans could be performed.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method